NBP 606

Drug Profile

NBP 606

Alternative Names: 13-valent pneumococcal vaccine conjugate - SK Bioscience; 13vPnC - SK Bioscience; NBP-606

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK Chemicals
  • Developer SK Bioscience
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Pneumococcal infections

Most Recent Events

  • 02 Jul 2018 SK Chemicals divested the vaccine business portfolio to a newly formed subsidiary SK Bioscience
  • 21 Apr 2016 NBP 606 is still in phase III trials for Pneumococcal infections (Prevention) in South Korea
  • 01 Mar 2015 SK Chemials completes a phase III trial in Pneumococcal infections (prevention, in elderly, treatment-naive) in South Korea (IM) (NCT02079207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top